IRVINE, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has received an update from INVIMA (the Colombian equivalent of the U.S. FDA) in Bogota on the status of […]
Peripheral/Endo
Endologix Honors Innovators of Aortic Therapy at VEITHsymposium
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today honored four innovators of aortic therapy at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium®), a meeting of endovascular specialists highlighting developments in the treatment of vascular disease. At an […]
New Findings Presented at the VEITHsymposium Reiterate Consistent, Durable Outcomes in Complex Aortic Disease with Heli-FX(TM) Endoanchor(TM) System
DUBLIN and NEW YORK – November 16, 2018 – Medtronic plc (NYSE:MDT) today announced new data on the Heli-FX(TM) EndoAnchor(TM) system, which demonstrated durability, safety and efficacy in patients with complex aortic abdominal aneurysm (AAA) anatomy, particularly those with hostile aortic neck anatomies. The new data were unveiled in presentations at the […]
First Patients in Europe Treated with Cardiovascular Systems, Inc. Peripheral Orbital Atherectomy System
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Germany have been treated with its Stealth 360® Peripheral Orbital Atherectomy System (OAS). The German cases […]
AngioSoma Creates New Partnership Opportunity
HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma (OTC: SOAN), a leading biotechnology research and development company, announces today the execution of a letter of intent to pursue a relationship with Biomedix®. Biomedix® manufactures a noninvasive device, PADnet, that diagnoses Peripheral Artery Disease (PAD) in patients. Biomedix […]
InspireMD Announces Upcoming Presentations at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)
TEL AVIV, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that the Company’s CGuard™ Embolic Prevention System will be featured in several podium […]
Medtronic Receives CE Mark Approval for the Valiant Navion(TM) Thoracic Stent Graft System
DUBLIN – November 13, 2018 – Medtronic plc (NYSE:MDT) today announced it has received CE Mark approval for the Valiant Navion(TM) thoracic stent graft system for the minimally invasive repair of all lesions of the descending thoracic aorta, including thoracic aortic aneurysms (TAA), blunt traumatic aortic injuries (BTAI), penetrating atherosclerotic ulcers (PAU), […]
Intact Vascular to Sponsor Post-Angioplasty Dissection Symposium and Present an Update on the TOBA II Pivotal Study Results at the 2018 VEITH Conference
WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a private medical device company committed to developing solutions for minimally invasive peripheral vascular procedures, today announced the schedule of key presentations to be featured during a lunch symposium co-sponsored with Philips at the 45th annual VEITH conference in New York City on Thursday, November 15th. […]
Philips announces first U.S. patient enrolled in ILLUMENATE study of Stellarex 0.014 Drug-Coated Balloon for below-the-knee peripheral artery disease
AMSTERDAM, Nov. 12, 2018 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced enrollment of the first U.S. patient in the Stellarex ILLUMENATE Below-the-Knee (BTK) Investigational Device Exemption (IDE) study, led by principal investigators Dr. Bill Gray and Dr. Mahmood K. Razavi. This unique global, prospective, randomized, multi-center trial is designed […]
Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors
CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following update on its research and development activities. Further to the Company’s press release dated November 8, 2018 where it discussed research and development initiatives and […]



